Johnson & Johnson
featured
After trying its products this Hollywood star bought an equity stake in the company. Could her endorsement lead to an IPO?
» Read More
More
-
Schering-Plough reported strong first-quarter results, surpassing consensus estimates by a wide margin due to robust sales of cholesterol drugs and allergy treatments.
-
Abbott Laboratories said on Wednesday its first-quarter earnings fell 19% as charges related to acquisitions and cost-cutting offset sharply higher sales of its prescription drugs and medical devices.
-
Cramer's got the call on Bank of America, Jones Soda, AIG and more.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
-
The Dow closed within striking distance of a new record following another batch of strong earnings reports. "I think this market is acting great," said Todd Leone head of listed trading at Cowen & Company. "We've had a tremendous rally and we’re still making a number of new highs. It's really acting well."
-
Johnson & Johnson beat the Street and raised its outlook for this year, but the hybrid Pharma/Consumer Products/Medical Devices company posted a much bigger drop in sales of its highly profitable drug-coated stents than analysts expected. Stents are the expensive, little wire mesh tubes that prop open clogged arteries. Recently, sales of stents coated with drugs have come under increasing scrutiny over safety.
-
Healthcare giant Johnson & Johnson reported quarterly earnings above Wall Street estimates and raised 2007 earnings guidance, sending shares up almost 3%.
-
Stocks are set to open higher, reversing an early negative trend, after consumer inflation data showed muted increases in core inflation. However, the CPI rose at a 0.6% rate when including food and energy, its highest rise since last April. Housing starts rose 0.8%, beating analysts expectatons but below February's increase.
-
Boston Scientific said on Monday it had resolved deficiencies that U.S. regulators had found at a plant that manufactures heart rhythm devices, sending its shares up nearly 7%.
-
The maker of the FluMist vaccine said it was putting istself up for sale, causing its shares to surge more than 10%. MedImmune also said that certain major drugmakers had already indicated they might be interested in a takeover.
-
Nobody stays best of breed forever. And no matter how you feel about a company's reputation, only the fundamentals matter at end of day. For that reason, you should never hesitate to clear a poor performer from your portfolio - no matter how much of a blue chip you think it is.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
-
The National Kidney Foundation said on Thursday it plans to cut its recommended target for hemoglobin levels in kidney disease patients -- a move that could hurt sales of lucrative anemia drugs that boost hemoglobin but have come under scrutiny over safety concerns.
-
Johnson & Johnson said it had withdrawn all lots of its Listerine Agent Cool Blue after determining that the product's preservative did not effectively control certain microorganisms.
-
Despite a volatile first quarter, stocks aren't much above where they were at the beginning of the year. But even if the major averages aren't showing big gains, smart investors know where to look for growth opportuntities.
-
A U.S. federal court has ruled that a stent made by Johnson and Johnson unit Cordis does not infringe a patent held by Boston Scientific, according to court documents.
-
This week's stock rally doesn't mean the market's recent pullback is over, money managers say.
-
There are two kinds of companies in the market – cyclical and secular. One of the most important moves in the game is to know when to shift your money from one to the other. Luckily, Cramer knows the precise moment.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.
-
In the second part of Cramer’s new series on non-pharma healthcare stocks, he sheds some light on this medical-imaging company.
-
Just when we thought it was safe to go back in the water, stocks implode again, today putting us on a crash course with the lows set last week.
-
Right now, the hottest part of the market is non-pharma health care because it is immunized from the subprime lending troubles. So each night this week Cramer will highlight one stock from the sector in hopes of finding you the next big thing.
-
Johnson & Johnson on Monday said it received three subpoenas from U.S. attorneys related to sales and marketing of three of its prescription drugs.